Questions with no answer at all. Not questions with no accepted answer — those are elsewhere.
The specifics, since they change the answer: minus 20 °C · survodutide. Somebody stated this to me confidently and I would like to check it before repeating it. I…
I have the same lot stored correctly as a comparator, if a side-by-side test would help. I have worked this out and I would like someone to find the error, because I…
What I am working with: orforglipron · phosphate-buffered diluent. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me…
I would like to know how much of this is established and how much is a reasonable story. I understand the observation; what I do not understand is the mechanism…
Setup, so nobody has to ask: SURMOUNT-1 · a GLP-1 receptor agonist. This has the shape of a fact but I cannot find its origin. What I found instead were three…
Stated plainly: FGP · mazdutide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all citing each other.…
The case in front of me: 1 mg/mL · liraglutide. I would like the axes of comparison first and the recommendation second. I have tried the first option and it works;…
The specifics, since they change the answer: tirzepatide · 40 °C. Somebody stated this to me confidently and I would like to check it before repeating it. I would…
What I am working with: 60 mg · two weeks · headache. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious. My…
This is the third vial from the same lot, so I can compare against two known-good ones. I suspect the usual explanation for this is wrong, or at least incomplete. I…
Stated plainly: SOUL · vomiting · 2.5 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I…
It has now persisted for three weeks, which is what moved this from tolerable to worth asking about. I can parse the result. I am less sure what it licenses me to…
The particulars: 4 mg · survodutide. I would like the mechanism, because I want to be able to reason about the cases nobody has written about. I have tried to reason…
The case in front of me: Homopeptide · tirzepatide. I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact. I want to know…
Details up front: mazdutide · REDEFINE-1. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how…
Details up front: Hangzhou · Ireland. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
The case in front of me: TFC · Wuxi · Poland. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like…
What I have: a GLP-1 receptor agonist · 2–8 °C. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I…
Details up front: albumin-to-creatinine ratio · dulaglutide. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a…
Numbers first: REDEFINE-1 · 10 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
My records go back to the first dose with dates, so I can reconstruct the timeline exactly. I suspect the honest answer is that it depends, in which case I would like…
For context, I am working with a 10 mg presentation and a 2 mL fill. I am trying to build something sustainable rather than something thorough that I will abandon. I…
Setup, so nobody has to ask: 98.4% · sampling plan. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
What I am working with: TRIUMPH-3 · injection-site erythema. I would like help reading this properly rather than being told what conclusion to reach. I have the full…